To Top

INVESTORS

Company Information

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity.

Stock Info

Corporate Presentation

Stock Chart

News and Events

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
January 9 2023 at 8:00 am - January 12 at 5:00 pm - UTC+0
November 15 2022 at 8:00 am - November 17 at 5:00 pm - UTC+0
April 8 2022 at 8:00 am - 5:00 pm - UTC+0
August 9 2021 at 8:00 am - August 10 at 5:30 pm - UTC+0
June 4 2021 at 12:00 am - June 8 at 11:59 pm - UTC+0
January 20 2021 at 10:30 am - 11:00 am - UTC+0

Press Releases

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy ...
Purple Biotech Reports Second Quarter 2026 Financial Results
New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240's anti-tumor activity, favorable sa...
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safe...
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples Established CAPTN-...
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded...
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3's advancement toward clinical-stage immunotherapy development SAB leverag...
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accel...
Purple Biotech Regains Compliance with Nasdaq
Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a...
Purple Biotech Announces CEO Transition
Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/...
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results
Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development ca...
Purple Biotech Announces Plan to Implement ADS Ratio Change
ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a...
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolon...
First | Previous | Next  | Last

SEC Filings

Shareholders' Meetings

Date Files
September 8, 2026 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
December 15, 2025 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS VOTING SLIP FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERs
April 5, 2025 VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS 2024 proxy 6k Purple Edgar1 Purple Biotech LTD VIF
August 8, 2024 VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS 2024 proxy 6k Purple Edgar1 Purple Biotech LTD VIF
June 15, 2023 VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS Report of Foreign Private Issuer Report of Foreign Private Issuer
August 25, 2022 ea163003-6k_purplebioEDGAR2_Bannerless Instructions-and-Voting-Card-for-2022-GM PURPLE-BIOTECH-LTD-VIF
Dec 22, 2021 Purple-Biotech-Ltd_6-K_Voting-Slip Purple-Biotech-Ltd_6-K_Notice-and-Proxy-Statement 17865-PURPLE-BIOTECH-LTD-KITOV-VIF

Email alerts

Corporate Governance

Purple Biotech Ltd.’s Board of Directors sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Corporate Governance Documents
Code of Ethics Download
Audit Committee Charter Download
Compensation Committee Charter Download
Audit Committee Compensation Committee
Independent Directors
Dr. Eric Rowinsky
Ido Agmon icon-member
Robert Gagnon icon-member-chair-person
Suzana Nahum-Zilberberg icon-member icon-member-chair-person
Yael Margolin icon-member
Non-independent Directors
Isaac Israel icon-member
Gil Efron
icon-memberMember icon-chair-personChair
Skip to content